Progyny (NASDAQ:PGNY) Insider Sells $39,137.40 in Stock

Posted by Brian Himes on Jun 6th, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Progyny Trading Up 1.5%

Shares of PGNY stock opened at $25.86 on Friday. The stock has a 50 day moving average of $20.58 and a 200 day moving average of $22.30. The stock has a market cap of $2.03 billion, a P/E ratio of 33.58, a P/E/G ratio of 2.25 and a beta of 1.03. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. During the same period last year, the business earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts predict that Progyny, Inc. will post 1.07 earnings per share for the current fiscal year.

Progyny declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in PGNY. Wellington Management Group LLP increased its position in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Progyny during the fourth quarter worth approximately $19,917,000. Barclays PLC increased its position in shares of Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after purchasing an additional 696,447 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. BTIG Research reduced their price target on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and lifted their price target for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Read Our Latest Report on PGNY

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.